Takeda Sells Seven Products to TevaBy
Takeda Pharmaceutical plans to sell 7 additional long-listed products (off-patent brand-name drugs) in Japan to Teva Takeda Yakuhin, a business venture established in April 2016 by Takeda and Teva Pharmaceutical Industries, for 28.5 billion yen ($257 million) on May 1, 2017. Takeda earlier transferred long-listed products including Blopress (candesartan), an anti-hypertension drug, Takepron (lansoprazole), an ulcer drug, and Basen (voglibose), a diabetes drug, to Teva Takeda Yakuhin when the business was established.
Takeda will sell the following additional products to Teva Takeda Yakuhin, which will be responsible for the information supply activities for these products as of the sale date on May 1, 2017: diabetes drugs, Actos and Actos OD tablets (pioglitazone hydrochloride), Sonias combination tablets (pioglitazone hydrochloride/glimepiride), and Metatact combination tablets (pioglitazone hydrochloride/metformin); anti-hypertension drugs, Ecard combination tablets (candesartan cilexetil/hydrochlorothiazide) and Unisia combination tablets (candesartan cilexetil/amlodipine); and the peptic ulcer drug, Takelda (fixed dose combination of low-dose aspirin/lansoprazole).
Source: Takeda Pharmaceutical